Category: MASH in Focus
Recent Data From the ESSENCE Trial on Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis
G&H What is the rationale for studying semaglutide for the treatment of metabolic dysfunction-associated steatohepatitis? NA Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that […]
Overview of Lean MASH and MASLD
G&H How should lean metabolic dysfunction-associated steatohepatitis be defined? VW By definition, if someone is labeled as having lean metabolic dysfunction-associated steatohepatitis (MASH), 2 criteria should […]
Insights Into Combination Therapy for Metabolic Dysfunction-Associated Steatohepatitis
G&H What are the main reasons for using combination therapy for metabolic dysfunction-associated steatohepatitis? MC Given the current landscape of efficacy across the different agents that […]
Utilization of Noninvasive Tests to Diagnose At-Risk Metabolic Dysfunction-Associated Steatohepatitis
G&H Why is it important to diagnose at-risk metabolic dysfunction-associated steatohepatitis? MN Metabolic dysfunction-associated steatohepatitis (MASH; formerly known as nonalcoholic steatohepatitis) is prevalent in the United […]